Dextromethorphan Plus Ultra Low‐Dose Quinidine Reduces Pseudobulbar Affect

To evaluate dextromethorphan combined with ultra low‐dose quinidine (DMq) for treating pseudobulbar affect (PBA) in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS).

[1]  R. Thisted,et al.  Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis , 2006, Annals of neurology.

[2]  H. Mitsumoto,et al.  Subcommittee of the American Academy of Neurology Evidence-based Review) : Report of the Quality Standards Management, and Cognitive/behavioral Impairment (an Amyotrophic Lateral Sclerosis: Multidisciplinary Care, Symptom Practice Parameter Update: the Care of the Patient With , 2022 .

[3]  P. Wedlund,et al.  Dextromethorphan: Enhancing its systemic availability by way of low‐dose quinidine‐mediated inhibition of cytochrome P4502D6 , 1992, Clinical pharmacology and therapeutics.

[4]  M. Kameyama,et al.  Pathologic laughing and crying treated with levodopa. , 1984, Archives of neurology.

[5]  J. Musacchio,et al.  Effects of dextromethorphan site ligands and allosteric modifiers on the binding of (+)-[3H]3-(-3-hydroxyphenyl)-N-(1-propyl)piperidine. , 1989, Molecular pharmacology.

[6]  F. Ponti,et al.  QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience , 2000, European Journal of Clinical Pharmacology.

[7]  F. Manes,et al.  Prevalence and clinical correlates of pathological affective display in Alzheimer's disease. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[8]  C. Wallesch,et al.  [Pathological laughing and crying]. , 2001, Fortschritte der Neurologie-Psychiatrie.

[9]  M. Thorpy,et al.  Treatment of “emotional incontinence” with levodopa , 1979, Neurology.

[10]  D. Choi.  Dextrorphan and dextromethorphan attenuate glutamate neurotoxicity , 1987, Brain Research.

[11]  J. Cummings,et al.  Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. , 2000, The Journal of neuropsychiatry and clinical neurosciences.

[12]  T L Munsat,et al.  Practice Parameter: The Care of the Patient with Amyotrophic Lateral Sclerosis (An Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 1999, Neurology.

[13]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[14]  G. Seliger,et al.  Fluoxetine improves emotional incontinence. , 1992, Brain injury.

[15]  N. Brooks.  Personality change after severe head injury. , 1988, Acta neurochirurgica. Supplementum.

[16]  Ware J.E.Jr.,et al.  THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .

[17]  R. Thisted,et al.  Validation of the CNS emotional lability scale for pseudobulbar affect (pathological laughing and crying) in multiple sclerosis patients , 2004, Multiple sclerosis.

[18]  A. Burns,et al.  Sertraline in stroke‐associated lability of mood , 1999, International journal of geriatric psychiatry.

[19]  S J Pocock,et al.  Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. , 1992, Statistics in medicine.

[20]  R. Schiffer,et al.  Review of pseudobulbar affect including a novel and potential therapy. , 2005, The Journal of neuropsychiatry and clinical neurosciences.

[21]  J. Schmahmann,et al.  Diagnosis and management of pathological laughter and crying. , 2006, Mayo Clinic proceedings.

[22]  R. Robinson,et al.  Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. , 1993, The American journal of psychiatry.

[23]  A. Ludolph,et al.  Amyotrophic lateral sclerosis. , 2012, Current opinion in neurology.

[24]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[25]  A. Feinstein,et al.  Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. , 1997, Archives of neurology.

[26]  J. P. Gallagher.  Pathologic laughter and crying in ALS: a search for their origin , 1989, Acta neurologica Scandinavica.

[27]  Z. Griliches,et al.  Econometric Models for Count Data with an Application to the Patents-R&D Relationship , 1984 .

[28]  L. Sheiner,et al.  The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships. , 1981, British Journal of Clinical Pharmacology.

[29]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[30]  R. Schiffer,et al.  Treatment of pathologic laughing and weeping with amitriptyline. , 1985, The New England journal of medicine.

[31]  D. V. von Cramon,et al.  Paroxetine versus citalopram treatment of pathological crying after brain injury. , 1999, Brain injury.

[32]  G. Andersen,et al.  Citalopram for post-stroke pathological crying , 1993, The Lancet.

[33]  H. Hanger.  Emotionalism after stroke , 1993, The Lancet.

[34]  R. Sufit,et al.  Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review) , 1999, Neurology.

[35]  R. Robinson,et al.  Pathological laughing and crying following traumatic brain injury. , 2004, The Journal of neuropsychiatry and clinical neurosciences.